What should a cancer center look like in an era of AI, genomics, complex patient populations, rising costs, and declining public trust in science?
Issue 46 – Dec. 13, 2013
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
The FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee voted in favor of Galleri to become the first multi-cancer detection test to receive regulatory approval.
The White House last week considered, but ultimately abandoned, a plan to create a panel that would review NIH grants in an effort to weed out projects the administration regards as “woke.”
My recent column about Merck’s television commercial for perioperative Keytruda left me with a question I could not shake.
Breast cancer treatment has changed dramatically over the past decade. One of the most important advances has been our growing ability to understand the biology of each patient’s cancer and use those insights to guide treatment decisions more precisely. That shift is helping make personalized cancer care a reality.
Heidi Overton, President Trump’s nominee for FDA Commissioner, defended the agency’s recent policy decisions reversing its hardball stance on flavored nicotine products, as she appeared in front of the Senate Committee on Health, Education, Labor, and Pensions on Sept 24.
